Table 7.
Results of the base case cost-effectiveness analysis (year 2010 values) from the social health insurance perspective (standard errors in parentheses)
| Type of surgery | Costs (€) | Incremental costs (€) | VTE events per person | Incremental effect(events avoided) | ICER(€ per event avoided) |
|---|---|---|---|---|---|
| THR |
|
|
|
|
|
| Rivaroxaban |
146.5 (14.2) |
17.8 (19.6) |
0.005 (0.002) |
0.007 (0.005) |
875 |
| Enoxaparin |
128.7 (14.9) |
|
0.012 (0.005) |
|
|
| TKR |
|
|
|
|
|
| Rivaroxaban |
20.7 (9.0) |
−27.3 (10.7) |
0.014 (0.005) |
0.020 (0.007) |
dominant |
| Enoxaparin | 48.0 (16.9) | 0.035 (0.009) |
THR = total hip replacement, TKR = total knee replacement, VTE = venous thromboembolism, ICER = incremental cost-effectiveness ratio.